HOPE - Life without Depression
 
Transcranial Magnetic Stimulation (TMS) is the first non-pharmacological treatment for Major Depressive Disorder (MDD) approved by the FDA. I am happy to share the following press release from Neuronetics, Inc, and proud to be a part of the TMS Center of Lexington, LLC. Our results treating patients with Major Depressive Disorder (MDD) have been extremely encouraging and we are poised to continue helping the patients in this city. Dr. Miranda.
 
About NeuroStar® Advanced Therapy
 
NeuroStar® Advanced Therapy is the established leader in TMS, a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the #1 physician-preferred TMS treatment for patients with MDD, and there are over 800 NeuroStar systems in 49 states.
 
With over 300 million covered lives, NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.
 
NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05).1 The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head. Long term durability of effect has not been established in a randomized controlled trial.
 
Malvern, Pa., October 9, 2017 - Neuronetics, Inc., a privately held medical device company widely recognized as the market-leader in transcranial magnetic stimulation (TMS) with its NeuroStar Advanced Therapy for depression, has been named a Health Care Innovator by the Philadelphia Business Journal. The award honors the organizations, people, products and programs bringing innovation to advance the health care and medical industries in the Greater Philadelphia region. 
 
"It is our mission to transform lives and meet the needs of the 300 million people worldwide living with depression," said Chris Thatcher, President and CEO of Neuronetics, Inc. "It is a tremendous honor to be recognized for the advancements we have made with our innovative NeuroStar therapy, and we will continue to change the face of depression treatment - helping patients transform their lives and achieve remission from depression."
 
With more than 1.5 million treatments delivered to date worldwide, NeuroStar Advanced Therapy was cleared by the FDA in 2008 as a safe and effective treatment for adult patients with Major Depressive Disorder who have not seen success with at least one antidepressant medication. The non-drug, non-invasive treatment uses magnetic pulses to stimulate areas of the brain that are underactive in depression.
 
Earlier this year, NeuroStar Advanced Therapy announced its next generation system as the first FDA-cleared transcranial magnetic stimulation treatment that can be delivered in under 19 minutes.* In addition to the updated treatment time and improvements in patient access with widespread insurance coverage, the new NeuroStar Advanced Therapy offers several unique and innovative capabilities compared to generic TMS devices, including High Performance Coil, 3D Laser Positioning, Contact Sensing and TrakStar™ Cloud. These advanced technology features provide physicians with real-time feedback and deliver reliable and consistent treatment. The next generation system helps health care providers deliver enhanced customer-centric care, allowing doctors to prescribe the right treatment dose and deliver it at the right location every time to ensure patients are given their best chance at remission from depression.
 
Because of its continued success and innovation in the industry, Neuronetics closed on a $15 million Series G funding round from investors earlier this year to broaden its U.S. commercial operations, expand patient access and fund additional clinical trials for the treatment of psychiatric disorders.
 
To see the complete 2017 Health Care Innovators Award Honorees list, visit the Philadelphia Business Journal's award page. For more information about NeuroStar Advanced Therapy, visit www.NeuroStar.com.
 
About Neuronetics, Inc.
 
Neuronetics, Inc. is a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in Malvern, PA, Neuronetics, Inc. is the leader in transcranial magnetic stimulation (TMS) with its development of NeuroStar® Advanced Therapy, a noninvasive form of neuromodulation. For more information, please visit www.neurostar.com.
 
NeuroStar® is a registered trademark of Neuronetics, Inc.
 
For more information and full safety and prescribing information, visit www.neurostar.com.

The following article "Transcranial Magnetic Stimulation Effective for Major Depressive Disorder, Generalized Anxiety Disorder" was published on May, 20016 on "Psychiatry Advisor" by Tori Rodriguez, MA, LPC. For the complete article with references, click here.

This recent study presented at the 2016 Annual Meeting of the American Psychiatric Association (APA) in Atlanta, Georgia, investigated the effects of Transcranial Magnetic Stimulation (TMS) on Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) symptoms in a private practice setting with a sample of 123 patients.

The patients showed a 76 to 79% response to treatment, with no notable adverse effects. Remission rates were between 53 and 73% of the patients, an 80% long-term remission rate was observed among those available for follow-up assessments over a period of more than 4 years. “These findings further establish TMS as a safe, effective and durable treatment option, both acutely and on a continued basis, for those who suffer from a high degree of symptom severity and/or do not gain relief from antidepressant medications,” concluded the authors.

 


This is an article published on October 31st, 2016 in Today.com. The article is interesting as it points to minimal signs that could indicate early stages of clinical depression. Please read the article here.

The six signs are:

• Changes in sleep patterns
• Your mind seems muddled
• You Worry Too Much and Think Too Much
• Your Weight Changed
• You’re Not as Engaged or Expressive
• You Hurt A Lot

Although the article only lists medication and psychotherapy as treatments Transcranial Magnetic Stimulation is an FDA-approved treatment for clinical depression since 2008.

The fact that you may have one or more of these symptoms and signs in this list, it does not automatically imply that you have clinical depression. It is recommended that you visit your doctor and voice your concerns.

depression4 sm


This is an NPR article published on April 21t, 2016 in npr.org. This is an interesting research on the use of TMS for autism in adults. You can listen to the 43 minute audio file here, and you can also read the full article here.

Following is a short excerpt of the article:

"As someone with autism spectrum disorder, John Elder Robison knows what it's like to feel emotionally removed from situations. Robison tells Fresh Air's Terry Gross that throughout his life people have told him, "There's this emotional language you're missing. There are stories in people's eyes. There are messages."

Robison didn't fully understand what they meant until he received transcranial magnetic stimulation, a noninvasive procedure in which areas of the brain are stimulated with electromagnetic fields to alter its circuitry.

Neurologist Alvaro Pascual-Leone, who treated Robison, explains TMS as a "tool that allows us to introduce a small amount of current into specific parts of the brain without having to use surgery to do so. ... By introducing current in it, we can probe the function of certain parts of the brain [and] we can even modify how different parts of the brain work.".. Continue reading the article here"

The patient wrote the book "Switched On"

 


On 7/9/2016, Channel 12 News of Cincinnati ran this segment on TMS (transcranial magnetic stimulation) for the treatment of adolescents with depression.  TMS was FDA cleared in 2008 for the treatment of adults with depression.  Studies are now underway to prove that TMS is just as safe and effective for adolescents suffering with depression.